(CE) Celanese - Overview
Stock: Acetyls, Engineered Polymers, Thermoplastics, Resins, Elastomers
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.25% |
| Yield on Cost 5y | 0.10% |
| Yield CAGR 5y | -54.17% |
| Payout Consistency | 94.7% |
| Payout Ratio | 3.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 54.8% |
| Relative Tail Risk | -9.24% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.07 |
| Alpha | -46.72 |
| Character TTM | |
|---|---|
| Beta | 1.844 |
| Beta Downside | 2.307 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.96% |
| CAGR/Max DD | -0.28 |
Description: CE Celanese January 09, 2026
Celanese Corporation (NYSE:CE) is a global chemical and specialty-materials producer that operates two primary segments. The Engineered Materials segment supplies a broad portfolio of high-performance polymers-including nylon, polypropylene, polyoxymethylene, liquid-crystal polymers, and thermoplastic elastomers-for end-markets such as automotive, medical devices, consumer electronics, and energy-storage systems. The Acetyl Chain segment manufactures acetyl-based intermediates (e.g., acetic acid, vinyl acetate monomer, ethylene-vinyl acetate resins) used in paints, coatings, adhesives, flexible packaging, and pharmaceutical applications. Products are sold under well-known brands like Zytel, Hytrel, and Santoprene, primarily through direct OEM relationships and a network of distributors.
Key operating metrics that analysts watch include • 2023 revenue of roughly $9.1 billion, with the Engineered Materials segment contributing about 55 % of total sales; • adjusted EBITDA margin hovering near 13 %-a level that reflects both pricing power in specialty polymers and exposure to volatile natural-gas feedstock costs; • capacity utilization rates of ~ 85 % across its U.S. and European plants, which can be a leading indicator of demand trends in automotive lightweighting and battery-case production. Macro-level drivers for Celanese are the global shift toward electrification (boosting demand for high-temperature polymers), cyclical construction activity (affecting polyphenylene sulfide and PVC-based products), and the price trajectory of natural gas, which accounts for roughly 30 % of its variable production costs.
For a deeper, data-driven view of Celanese’s valuation and risk profile, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -3.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.36 > 1.0 |
| NWC/Revenue: 24.34% < 20% (prev 14.76%; Δ 9.57% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.39b > Net Income -3.09b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (109.6m) vs 12m ago 0.06% < -2% |
| Gross Margin: 21.33% > 18% (prev 0.23%; Δ 2110 % > 0.5%) |
| Asset Turnover: 40.41% > 50% (prev 40.47%; Δ -0.06% > 0%) |
| Interest Coverage Ratio: -2.86 > 6 (EBITDA TTM -1.28b / Interest Expense TTM 719.0m) |
Altman Z'' 2.11
| A: 0.11 (Total Current Assets 6.09b - Total Current Liabilities 3.73b) / Total Assets 22.17b |
| B: 0.44 (Retained Earnings 9.86b / Total Assets 22.17b) |
| C: -0.09 (EBIT TTM -2.06b / Avg Total Assets 24.03b) |
| D: 0.51 (Book Value of Equity 9.01b / Total Liabilities 17.79b) |
| Altman-Z'' Score: 2.11 = BBB |
Beneish M -3.38
| DSRI: 0.89 (Receivables 1.70b/2.06b, Revenue 9.71b/10.48b) |
| GMI: 1.09 (GM 21.33% / 23.19%) |
| AQI: 0.86 (AQ_t 0.48 / AQ_t-1 0.55) |
| SGI: 0.93 (Revenue 9.71b / 10.48b) |
| TATA: -0.20 (NI -3.09b - CFO 1.39b) / TA 22.17b) |
| Beneish M-Score: -3.38 (Cap -4..+1) = AA |
What is the price of CE shares?
Over the past week, the price has changed by +23.49%, over one month by +23.35%, over three months by +51.98% and over the past year by -20.14%.
Is CE a buy, sell or hold?
- StrongBuy: 5
- Buy: 0
- Hold: 12
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52.2 | -4.9% |
| Analysts Target Price | 52.2 | -4.9% |
| ValueRay Target Price | 53.9 | -1.8% |
CE Fundamental Data Overview February 03, 2026
P/S = 0.5012
P/B = 1.2584
P/EG = 4.4198
Revenue TTM = 9.71b USD
EBIT TTM = -2.06b USD
EBITDA TTM = -1.28b USD
Long Term Debt = 11.65b USD (from longTermDebt, last quarter)
Short Term Debt = 1.20b USD (from shortTermDebt, last quarter)
Debt = 13.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.69b USD (from netDebt column, last quarter)
Enterprise Value = 16.56b USD (4.87b + Debt 13.13b - CCE 1.44b)
Interest Coverage Ratio = -2.86 (Ebit TTM -2.06b / Interest Expense TTM 719.0m)
EV/FCF = 16.17x (Enterprise Value 16.56b / FCF TTM 1.02b)
FCF Yield = 6.18% (FCF TTM 1.02b / Enterprise Value 16.56b)
FCF Margin = 10.55% (FCF TTM 1.02b / Revenue TTM 9.71b)
Net Margin = -31.85% (Net Income TTM -3.09b / Revenue TTM 9.71b)
Gross Margin = 21.33% ((Revenue TTM 9.71b - Cost of Revenue TTM 7.64b) / Revenue TTM)
Gross Margin QoQ = 21.54% (prev 21.13%)
Tobins Q-Ratio = 0.75 (Enterprise Value 16.56b / Total Assets 22.17b)
Interest Expense / Debt = 1.35% (Interest Expense 177.0m / Debt 13.13b)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.63b (EBIT -2.06b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.63 (Total Current Assets 6.09b / Total Current Liabilities 3.73b)
Debt / Equity = 3.32 (Debt 13.13b / totalStockholderEquity, last quarter 3.95b)
Debt / EBITDA = -9.10 (negative EBITDA) (Net Debt 11.69b / EBITDA -1.28b)
Debt / FCF = 11.42 (Net Debt 11.69b / FCF TTM 1.02b)
Total Stockholder Equity = 4.90b (last 4 quarters mean from totalStockholderEquity)
RoA = -12.87% (Net Income -3.09b / Total Assets 22.17b)
RoE = -63.15% (Net Income TTM -3.09b / Total Stockholder Equity 4.90b)
RoCE = -12.44% (EBIT -2.06b / Capital Employed (Equity 4.90b + L.T.Debt 11.65b))
RoIC = -9.20% (negative operating profit) (NOPAT -1.63b / Invested Capital 17.69b)
WACC = 4.21% (E(4.87b)/V(18.00b) * Re(12.71%) + D(13.13b)/V(18.00b) * Rd(1.35%) * (1-Tc(0.21)))
Discount Rate = 12.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.05%
[DCF Debug] Terminal Value 84.22% ; FCFF base≈952.0m ; Y1≈788.6m ; Y5≈572.9m
Fair Price DCF = 53.20 (EV 17.52b - Net Debt 11.69b = Equity 5.83b / Shares 109.5m; r=5.90% [WACC]; 5y FCF grow -20.68% → 2.90% )
EPS Correlation: -80.35 | EPS CAGR: -58.50% | SUE: -3.88 | # QB: 0
Revenue Correlation: 9.64 | Revenue CAGR: 1.65% | SUE: -1.42 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.92 | Chg30d=-0.029 | Revisions Net=-4 | Analysts=10
EPS next Year (2026-12-31): EPS=5.44 | Chg30d=-0.118 | Revisions Net=-5 | Growth EPS=+27.9% | Growth Revenue=-0.1%